PEI expert for vaccines and biomedicines elected as member of the EMA's Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use at the European Medicines Agency assesses new medicinal products and gives recommendations in favour of or against European marketing authorisations to the European Commission. Dr Jan Müller-Berghaus, expert for vaccines and biomedicines at the Paul-Ehrlich-Institut (PEI) renewed his candidacy for membership at the CHMP which was confirmed as per 9 November 2017 for another three years.
Safe blood products – PEI develops WHO-reference materials for platelet concentrates
Testing of blood products for pathogenic agents is an important pillar of blood product safety. Researchers of the Paul-Ehrlich-Institut (PEI) have extended the repository of reference strains for the testing of platelet concentrates as part of their role as Collaborating Centre for the World Health Organization by ten bacterial strains.
Mode of action of the vaccine adjuvant flagellin in fusion proteins has been clarified
Fusion proteins consisting of antigens and the bacterial adjuvant flagellin are promising vaccine candidates. They have the protential to induce immune responses in a targeted and reliable manner, thus conveying protection against infectious diseases. In addition, they can favourably influence misdirected immune reactions, for example as part of a treatment against allergies.